Your browser doesn't support javascript.
loading
Current and Future Directions for Angiosarcoma Therapy.
Florou, Vaia; Wilky, Breelyn A.
Afiliação
  • Florou V; University of Miami Sylvester Comprehensive Cancer Center, 1475 NW 12th Avenue, Suite 3300 (D8-4), Miami, FL, 33136, USA.
  • Wilky BA; University of Miami Sylvester Comprehensive Cancer Center, 1475 NW 12th Avenue, Suite 3300 (D8-4), Miami, FL, 33136, USA. b.wilky@miami.edu.
Curr Treat Options Oncol ; 19(3): 14, 2018 03 08.
Article em En | MEDLINE | ID: mdl-29520447
OPINION STATEMENT: Angiosarcomas are rare vascular neoplasms that are among the most aggressive subtypes of soft tissue sarcomas. Surgical resection is often challenging even in localized disease, as the infiltrative nature of these cancers leads to frequent local and metastatic recurrences. Cytotoxic chemotherapy, including anthracycline-based regimens and taxanes can produce significant responses in a subset of patients but durability is limited with most patients ultimately succumbing to metastatic disease. Targeted therapy with tyrosine kinase inhibitors is usually well-tolerated but prone to development of resistance. Few head-to-head trials have addressed the optimal sequence of therapies, or demonstrated conclusive benefits of one therapy over another based on clinical and etiologic factors. Novel therapies in clinical trials, including antibodies to endoglin and checkpoint inhibitors have demonstrated exciting early activity in patients with angiosarcoma. Improved understanding of the genetic heterogeneity within various angiosarcoma subtypes may identify predictive biomarkers to match patients to effective existing and future therapies. Overall, angiosarcoma patients with optimal performance status are best served in clinical trials that incorporate novel combinations of cytotoxic chemotherapy, targeted therapies, and immunotherapies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sarcoma / Terapia de Alvo Molecular / Hemangiossarcoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sarcoma / Terapia de Alvo Molecular / Hemangiossarcoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article